CN107693773A - 一种大蒜糖肽组合物 - Google Patents
一种大蒜糖肽组合物 Download PDFInfo
- Publication number
- CN107693773A CN107693773A CN201710880740.2A CN201710880740A CN107693773A CN 107693773 A CN107693773 A CN 107693773A CN 201710880740 A CN201710880740 A CN 201710880740A CN 107693773 A CN107693773 A CN 107693773A
- Authority
- CN
- China
- Prior art keywords
- garlic
- glycopeptide
- resveratrol
- composition
- grams
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108010015899 Glycopeptides Proteins 0.000 title claims abstract description 77
- 102000002068 Glycopeptides Human genes 0.000 title claims abstract description 77
- 235000004611 garlic Nutrition 0.000 title claims abstract description 77
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 title claims abstract description 65
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 244000245420 ail Species 0.000 title 1
- 240000002234 Allium sativum Species 0.000 claims abstract description 76
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 57
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 55
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract description 55
- 229940016667 resveratrol Drugs 0.000 claims abstract description 55
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 239000007938 effervescent tablet Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000007919 dispersible tablet Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 10
- 230000009286 beneficial effect Effects 0.000 abstract description 8
- 230000036541 health Effects 0.000 abstract description 8
- 239000004480 active ingredient Substances 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 abstract description 3
- 241000050051 Chelone glabra Species 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 description 18
- 238000000227 grinding Methods 0.000 description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 239000003826 tablet Substances 0.000 description 12
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 10
- 239000000314 lubricant Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 239000007962 solid dispersion Substances 0.000 description 8
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 7
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 239000001569 carbon dioxide Substances 0.000 description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 description 5
- 239000002270 dispersing agent Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- -1 polyphenol compound Chemical class 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 235000015165 citric acid Nutrition 0.000 description 4
- 229960003511 macrogol Drugs 0.000 description 4
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 235000012907 honey Nutrition 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 229940080313 sodium starch Drugs 0.000 description 3
- 239000008279 sol Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- OEGPRYNGFWGMMV-UHFFFAOYSA-N (3,4-dimethoxyphenyl)methanol Chemical compound COC1=CC=C(CO)C=C1OC OEGPRYNGFWGMMV-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 244000037364 Cinnamomum aromaticum Species 0.000 description 2
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229930182473 O-glycoside Natural products 0.000 description 2
- 150000008444 O-glycosides Chemical class 0.000 description 2
- AQLLBJAXUCIJSR-UHFFFAOYSA-N OC(=O)C[Na] Chemical compound OC(=O)C[Na] AQLLBJAXUCIJSR-UHFFFAOYSA-N 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 description 2
- 240000006365 Vitis vinifera Species 0.000 description 2
- 235000014787 Vitis vinifera Nutrition 0.000 description 2
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 235000019477 peppermint oil Nutrition 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 235000020095 red wine Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000020374 simple syrup Nutrition 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 235000014101 wine Nutrition 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WRFYIYOXJWKONR-UHFFFAOYSA-N 4-bromo-2-methoxyaniline Chemical compound COC1=CC(Br)=CC=C1N WRFYIYOXJWKONR-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 238000010669 acid-base reaction Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000320 anti-stroke effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003130 cardiopathic effect Effects 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940124444 chemoprotective agent Drugs 0.000 description 1
- 235000019987 cider Nutrition 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 235000006486 human diet Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000008604 lipoprotein metabolism Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000019520 non-alcoholic beverage Nutrition 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008201 pharmaceutical excipient composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000020097 white wine Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Botany (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明具体公开了一种大蒜糖肽组合物，其技术特征是由大蒜糖肽与白藜芦醇及药用辅料组成，其中大蒜糖肽与白藜芦醇的用量的重量比为：大蒜糖肽：白藜芦醇＝5‑80：1。本发明的大蒜糖肽与白藜芦醇组合物能有效地将两种天然有机活性成分进行优化组合，充分发挥大蒜糖肽与白藜芦醇的活性成分功效，对组合配比的应用可有益地作为保健性的天然活性成分制备的口服制剂，更有益于量化，使服用剂量准确，同时也为组合物的应用增加新的制剂和品种，利于民众的选择使用。本发明产品具有较好的经济效益前景。
Description
技术领域
本发明涉及一种功能性食品天然成分组合物，具体涉及含有大蒜糖肽和白藜芦醇的药物组合物。
背景技术
随着社会经济的发展，人们生活水平的提高，其饮食结构发生了很大改变，由于食物中的脂肪和热量增加，生活条件相对优越，体力活动相对减少，一些所谓的“富贵病”也随之增加。如心脑血管系统疾病的发病率逐年上升、高血糖和高血脂疾病及免疫力低下等已成为临床的常见和多发病。然而，随着教育水平、医学知识和健康保健知识的提高，国民的健康意识日益增强，越来越多的民众已经对自己和家人的身体健康更加关注，一些添加了天然的具有功能性的制品日益受到欢迎。
在防治心脑血管疾病、改善血糖和调节血脂、提高人体免疫力等方面，目前大多仍采用药物性治疗，这不仅使民众增加了医疗负担，且在治疗中产生诸多副作用，同样影响着人们的身体和精神健康。就目前从植物提取物中能够预防或治疗这些疾病的功能性原料有很多，从中筛选能够达到预防此类疾病发生的原料进行优化组合，且制备成利于服用的制剂，使人们易于接受服用，以达到生理调理治疗“未病”的发生，这将是对民众健康事业是有益的。大蒜糖肽、白藜芦醇就是其中的全天然功能性原料。糖肽连键是指由单糖的异碳与羟基氨基酸的羟基O原子共价结合而成的O-糖苷键。大蒜糖肽是大蒜中具有生物活性肽特性的有益成分，具有很强的活性，其活性肽能对人体产生很好的免疫调节和新陈代谢作用。活性糖肽是涉及人体内多种细胞功能的重要物质，具有调节细胞功能活性的功能。在人体作为神经递质，传递信息。可在人体作为运输工具，将人体所食的各种营养物质与各种维生素、生物素、钙及对人体有益的微量元素输送到人体各细胞、器官和组织。糖肽是人体重要的生理调节物，它可全面调节人体生理功能，增强和发挥人体生理活性，具有重要的生物学功能。
白藜芦醇是由植物中提取的一种多酚类化合物，是心、脑血管疾病的天然预防剂，大量研究表明白藜芦醇具有抗炎、抗过敏、抗血栓、抗动脉粥样硬化和冠心病缺血性心脏病、高血脂症的预防作用，还具有抗氧化、抗自由基的作用。科学研究证实：白藜芦醇可有效预防中风和冠心病；同时具有降血脂、抑制血小板聚集及调节脂蛋白等作用。一些流行病学的研究显示：通过适量饮酒特别是饮红葡萄酒能降低冠心病的死亡率，可能是酒中所含的白藜芦醇起了预防心脏病的作用，有报道它可以抑制血小板聚集及调节脂蛋白的代谢。白藜芦醇在新鲜葡萄皮及其加工之后的食品中的含量很高，在红葡萄酒中含量可高达1.5-3㎎.L-¹，在白葡萄酒和玫瑰酒中的含量也相对可观。人类饮食中的常见成分白藜芦醇也成了学者们作为化学防癌剂进行深入研究。但长期饮葡萄酒对身体有不良影响，白藜芦醇的来源应当是食品和非酒精的饮料或其他剂型制品。
发明内容
本发明的目在于提供一种大蒜糖肽和白藜芦醇组成的复方制剂，该大蒜糖肽组合物，既保持了大蒜糖肽和白藜芦醇的保健功效，也大大丰富了保健制品品种，适宜民众方便使用和选择。
为了实现本发明，具体采用了以下技术方案：
本发明提供的大蒜糖肽与白藜芦醇药物组合物，其特征在于它由大蒜糖肽和白藜芦醇及药用赋形剂组成，其中，大蒜糖肽和白藜芦醇的用量之比例为：大蒜糖肽：白藜芦醇=5~80：1。
本发明提供的大蒜糖肽与白藜芦醇药物组合物，大蒜糖肽和白藜芦醇的用量之比优选为：大蒜糖肽：白藜芦醇=10~60:1。
本发明提供的大蒜糖肽与白藜芦醇药物组合物，大蒜糖肽和白藜芦醇的用量之比最优选为：大蒜糖肽：白藜芦醇=35:1。
本发明中的大蒜糖肽和白藜芦醇均为植物中提取的有机活性成分，能产生不同活性成分、不同作用机制功效和协同效果，这对均具有维持心血管健康、维持正常血糖、血脂水平、支持脂肪代谢、支持健康的免疫功能、增强机体免疫能力的活性成分组合制成复方制剂，对扩大药物间的配伍应用，提供新的供民众选择的产品很有实用意义。
本发明除另有说明的，所述的用量比均为重量比。
本发明提供的大蒜糖肽和白藜芦醇药物组合物用于配制成口服剂型，可以配制成分散片、泡腾片、片剂、胶囊、软胶囊、颗粒和口服液等，优选分散片和泡腾片，因为分散片与普通片剂相比有如下几点优势：（1）服用方便：可化水，也可当普通片剂服用，便于老年人服用；（2）吸收快，生物利用度高；（3）便于携带、运输。泡腾片与普通片剂相比有如下几点优势：（1）泡腾片当与水接触时，酸碱反应生成二氧化碳气体，促使整个片剂在短时间内溶解；（2）口服泡腾片特别适宜儿童、老年人和不能吞服固体制剂的患者；（3）由于泡腾片中加入有矫味剂，使人们服用适口，利于服用；（4）又因以溶液剂形式服用，药物起效迅速，生物利用度高；（5）与液体制剂相比，携带更为方便。用大蒜糖肽和白藜芦醇组合物制备制剂时，应包括指定用量的大蒜糖肽和白藜芦醇以及在药物制备中常规使用的辅料，其制备过程也均采用本技术领域中的常规制备方法，如分散片可包括作为载体的分散剂、表面活性剂、稀释剂、崩解剂、润滑剂、粘合剂等。再如泡腾片可包括作为酸源（如柠檬酸、酒石酸、苹果酸、水溶性氨基酸等）、二氧化碳源（碳酸钠、碳酸氢钠、碳酸钾、碳酸氢钾、碳酸钙等）、粘合剂、甜味剂（如蔗糖、糖精钠、甜蜜素、蛋白糖、环乙烷氨基磺酸（钠）等）、润滑剂、矫味剂（如各种香精、各种果味料等）。
本发明除另有说明的，所述的用量比例均为重量比。
糖肽连键是指由单糖的异碳与羟基氨基酸的羟基O原子共价结合而成的O-糖苷键，大蒜糖肽是大蒜中具有生物活性肽特性的有益成分，具有很强的活性，其活性肽能对人体产生很好的免疫调节和新陈代谢作用。活性糖肽是涉及人体内多种细胞功能的重要物质，具有调节细胞功能活性的功能。在人体作为神经递质，传递信息。可在人体作为运输工具，将人体所食的各种营养物质与各种维生素、生物素、钙及对人体有益的微量元素输送到人体各细胞、器官和组织。糖肽是人体重要的生理调节物，它可全面调节人体生理功能，增强和发挥人体生理活性，具有重要的生物素功能。本发明采用的大蒜糖肽是由本发明申请人母公司（徐州绿之野生物食品有限公司）依据国家专利（专利号：ZL201310580196.1）开发的原料产品，具体制备方法是按该发明实施例8的操作步骤方法制得，具体的步骤是将实施例 7 得到的大蒜蛋白粉加纯净水，使成大蒜蛋白在水中的重量浓度为 2.5-10%、 加热至30-65℃，调节 PH 值为 6.6-7.2 之间进行溶解后，加入大蒜蛋白溶液重量的 1-3% 的中性蛋白酶进行第一次酶解，酶解条件是控制 PH 为 6.5-6.9，保温 45-55℃、酶解时间为3-4.5 小时，然后将中性蛋白酶解液再加入复合风味蛋白酶进行二次酶解，其条件是复合风味蛋白酶的重量为大蒜蛋白溶液重量的 1.0-2.5%，PH 值自然，保温 49-52℃，酶解时间为 4-7.5 小时，得酶解液，然后将酶解液用 1moL/L 盐酸调节 PH 值在 4.2-4.4 之间，静置沉淀使 自然冷却后，进行离心分离得上清液和沉淀物 ；将上清液加入复混蛋白酶的重量为上清液 重量的 1.6-2.8% 进行第三次酶解，第三次酶解控制 PH 值为 6.5-7.0、温度46-52℃，时间为 5.5-7.5 小时，然后 98℃灭酶，经浓缩、喷雾干燥得大蒜糖肽。当然，在ZL201310580196.1实施例8的操作过程中，发明人是对整个发明方案过程是全面了解和掌握的，目前对实施该专利产品的过程中，其工艺是成熟的，产品是稳定的。
本发明一种大蒜糖肽与白藜芦醇组合物能有效地将两种天然有机活性成分进行优化组合，充分发挥大蒜糖肽与白藜芦醇的活性成分功效，对组合配方的应用可有益地作为保健性的天然活性成分制备成口服制剂，更有益于量化，使服用量剂量准确，同时也为组合物的应用增加了新的制剂和品种，更有利于民众的选择使用。
4、具体实施方式
以下实施例是对本发明作出进一步的实施详细的叙述，并非对本发明范围的限制，也不是本发明的全部，对本领域的技术人员来说，在不脱离本发明方案技术原理的前提下进行的改进和润饰均视为本发明的保护范围。
实施例1
称取10克大蒜糖肽和2克白藜芦醇混合研磨均匀，然后加入药用赋形剂（如淀粉、羧甲基淀粉钠、交联羧甲基纤维素钠、纤维素、交联聚维酮、糊精等），按常规片剂制法制成约1000片的复方大蒜糖肽片。
实施例2
称取80克大蒜糖肽和1克白藜芦醇混合研磨均匀，然后加入药用赋形剂（淀粉、羧甲基淀粉钠、交联羧甲基纤维素钠、纤维素、交联聚维酮、糊精等），按常规片剂制法制成约1000片的复方大蒜糖肽片。
实施例3
称取50克大蒜糖肽和5克白藜芦醇混合研磨均匀，然后加入药用赋形剂（淀粉、羧甲基淀粉钠、交联羧甲基纤维素钠、纤维素、交联聚维酮、糊精等），按常规片剂制法制成约1000片的复方大蒜糖肽片。
实施例4
称取70克大蒜糖肽和2克白藜芦醇混合研磨均匀，然后加入适量的分散剂（如聚乙烯吡咯烷酮、交联聚乙烯吡咯烷酮、聚乙二醇4000、聚乙二醇6000等）研磨得固体分散体，称取处方量的其他片剂辅料与固体分散体按等量递加法混合均匀，加入助流剂及润滑剂，混匀、压片、制成约1000片的复方大蒜糖肽片。
实施例5
称取80克大蒜糖肽和10克白藜芦醇混合研磨均匀，然后加入适量的分散剂（如聚乙烯吡咯烷酮、交联聚乙烯吡咯烷酮、聚乙二醇4000、聚乙二醇6000等）研磨得固体分散体，称取处方量的其他片剂辅料与固体分散体按等量递加法混合均匀，加入助流剂及润滑剂，混匀、压片、制成约1000片的复方大蒜糖肽片。
实施例6
称取35克大蒜糖肽和1克白藜芦醇混合研磨均匀，然后加入适量的分散剂（如聚乙烯吡咯烷酮、交联聚乙烯吡咯烷酮、聚乙二醇4000、聚乙二醇6000等）研磨得固体分散体，称取处方量的其他片剂辅料与固体分散体按等量递加法混合均匀，加入助流剂及润滑剂，混匀、压片、制成约1000片的复方大蒜糖肽片。
实施例7
称取10克大蒜糖肽和1克白藜芦醇混合研磨均匀，然后加入适量的分散剂（如聚乙烯吡咯烷酮、交联聚乙烯吡咯烷酮、聚乙二醇4000、聚乙二醇6000等）研磨得固体分散体，称取处方量的其他片剂辅料与固体分散体按等量递加法混合均匀，加入助流剂及润滑剂，混匀、压片、制成约1000片的复方大蒜糖肽片。
实施例8
称取35克大蒜糖肽和7克白藜芦醇混合研磨均匀，然后取适量的酸源（如：柠檬酸等）、二氧化碳源（如：碳酸氢钠等）分别干燥过筛混合成泡腾剂，与上述研磨均匀后的原料混合，再称取处方量的甜味剂、矫味剂与之混合均匀，加入助流剂及润滑剂，混合压片，制成约1000片的复方大蒜糖肽片。
实施例9
称取40克大蒜糖肽和5克白藜芦醇混合研磨均匀，然后取适量的酸源（如：柠檬酸等）、二氧化碳源（如：碳酸氢钠等）分别干燥过筛混合成泡腾剂，与上述研磨均匀后的原料混合，再称取处方量的甜味剂、矫味剂与之混合均匀，加入助流剂及润滑剂，混合压片，制成约1000片的复方大蒜糖肽片。
实施例10
称取50克大蒜糖肽和2克白藜芦醇混合研磨均匀，然后取适量的酸源（如：柠檬酸等）、二氧化碳源（如：碳酸氢钠等）分别干燥过筛混合成泡腾剂，与上述研磨均匀后的原料混合，再称取处方量的甜味剂、矫味剂与之混合均匀，加入助流剂及润滑剂，混合压片，制成约1000片的复方大蒜糖肽片。
实施例11
称取80克大蒜糖肽和4克白藜芦醇，然后取处方量的蒸馏水和处方量的矫味剂（如甜味剂：蜂蜜、果汁糖浆、单糖浆等，如芳香剂：薄荷油、桂皮油、橙皮油、香精等）按常规方法制成1000毫升复方大蒜糖肽口服液。
实施例12
称取30克大蒜糖肽和3克白藜芦醇，然后取处方量的蒸馏水和处方量的矫味剂（如甜味剂：蜂蜜、果汁糖浆、单糖浆等，如芳香剂：薄荷油、桂皮油、橙皮油、香精等）按常规方法制成1000毫升复方大蒜糖肽口服液。
Claims (7)
1.一种大蒜糖肽与白藜芦醇药物组合物，其特征在于，它由大蒜糖肽和白藜芦醇及药用赋形剂组成，其中，大蒜糖肽和白藜芦醇的用量之比为：大蒜糖肽：白藜芦醇=5～80:1。
2.如权利要求1所述的大蒜糖肽与白藜芦醇药物组合物，大蒜糖肽和白藜芦醇的用量之比为：大蒜糖肽：白藜芦醇=10～60:1。
3.如权利要求1所述的大蒜糖肽与白藜芦醇药物组合物，大蒜糖肽和白藜芦醇的用量之比为：大蒜糖肽：白藜芦醇=35:1。
4.如权利要求1所述的大蒜糖肽与白藜芦醇药物组合物，其用于配制成口服剂型。
5.根据权利要求4所述的大蒜糖肽与白藜芦醇药物组合物，其用于配制成片剂、胶囊剂、软胶囊剂、颗粒剂和口服液。
6.根据权利要求5所述的大蒜糖肽与白藜芦醇药物组合物，其用于配制成分散片。
7.根据权利要求5所述的大蒜糖肽与白藜芦醇药物组合物，其用于配制成泡腾片。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710880740.2A CN107693773A (zh) | 2017-09-26 | 2017-09-26 | 一种大蒜糖肽组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710880740.2A CN107693773A (zh) | 2017-09-26 | 2017-09-26 | 一种大蒜糖肽组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107693773A true CN107693773A (zh) | 2018-02-16 |
Family
ID=61176096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710880740.2A Withdrawn CN107693773A (zh) | 2017-09-26 | 2017-09-26 | 一种大蒜糖肽组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107693773A (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101686725A (zh) * | 2007-04-03 | 2010-03-31 | 刚迦·拉贾·高卡拉贾 | 消炎和抗氧化协同作用的膳食补充组合物 |
| CN102088971A (zh) * | 2008-10-23 | 2011-06-08 | 达沃斯生命科学有限公司 | 生育三烯酚组合物预防癌症的用途 |
| CN102657866A (zh) * | 2012-05-06 | 2012-09-12 | 苟春虎 | 防癌抗癌胶囊 |
| CN103933024A (zh) * | 2014-04-04 | 2014-07-23 | 卢凯华 | 用于抗肿瘤的脂质体组合物 |
-
2017
- 2017-09-26 CN CN201710880740.2A patent/CN107693773A/zh not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101686725A (zh) * | 2007-04-03 | 2010-03-31 | 刚迦·拉贾·高卡拉贾 | 消炎和抗氧化协同作用的膳食补充组合物 |
| CN102088971A (zh) * | 2008-10-23 | 2011-06-08 | 达沃斯生命科学有限公司 | 生育三烯酚组合物预防癌症的用途 |
| CN102657866A (zh) * | 2012-05-06 | 2012-09-12 | 苟春虎 | 防癌抗癌胶囊 |
| CN103933024A (zh) * | 2014-04-04 | 2014-07-23 | 卢凯华 | 用于抗肿瘤的脂质体组合物 |
Non-Patent Citations (2)
| Title |
|---|
| GAGANDEEP KAUR等: "GarlicandResveratrolAttenuateDiabeticComplications,Lossofb-Cells,PancreaticandHepaticOxidativeStressinStreptozotocin-InducedDiabeticRats", 《FRONTIERS IN PHARMACOLOGY》 * |
| 黄蕾蕾等: "大蒜提取物的药理作用与临床应用", 《HERALD OF MEDICINE》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105248820B (zh) | 辣木叶与红糖的组合物及其制备方法和应用 | |
| CN103947967B (zh) | 双色黑红果枸杞片及其制备方法 | |
| KR101433188B1 (ko) | 아미노산, 활성종합비타민 및 한방생약재를 함유하는 숙취해소용 조성물 및, 그 제조방법 | |
| CN102224891B (zh) | 一种糖醇蜂蜜苹果酱及其制备方法 | |
| US9950024B2 (en) | Traditional Chinese medicine composition and the use thereof | |
| CN107149068A (zh) | 一种蜂蜜醒酒饮料及其制备方法 | |
| CN108085234A (zh) | 一种刺梨醋饮料的制备方法 | |
| CN105533574A (zh) | 一种排毒纤体青梅果及其制作工艺 | |
| CN103653144A (zh) | 提高免疫力的保健饮料其制备方法 | |
| CN107173656A (zh) | 一种中药果蔬益生菌发酵饮品及其制备方法 | |
| CN106070626A (zh) | 酸马奶水果饮料及其制备方法 | |
| CA2530216A1 (en) | The use of an edible acid or the potassium or sodium salt thereof in the treatment of allergy | |
| CN101099526B (zh) | 人参花保健茶饮料及其制备方法 | |
| CN106929367A (zh) | 一种淡竹叶酒及其制备工艺方法 | |
| KR101394358B1 (ko) | 숙취 해소용 조성물 | |
| CN105029553A (zh) | 一种果汁蛋钙中药保健饮料及其制备方法 | |
| CN104643078A (zh) | 一种复方铁皮石斛保健口服液及其制备方法 | |
| CN101884408B (zh) | 一种银杏叶浸提液及其制备方法 | |
| CN104068112A (zh) | 苦瓜葛根酸奶及其制备方法 | |
| KR101642176B1 (ko) | 성장촉진 조성물 | |
| CN1939155A (zh) | 一种保健饮品 | |
| CN107550896A (zh) | 一种蒜氨酸组合物 | |
| CN104605063A (zh) | 一种洛神消暑茶包的制备方法 | |
| KR20190140737A (ko) | 디톡스-다이어트 물질을 포함하는 식초 조성물의 제조방법 | |
| CN107581609A (zh) | 一种大蒜多肽组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180216 |